SNAP-8

Typical use cases

Dosing guidelines

Titration

Not typically titrated. Topical use is generally described as a fixed twice-daily application rather than a stepped dose escalation; some users are described as introducing it gradually alongside other actives to gauge skin tolerance.

Reconstitution

For lyophilized research powder, commonly described as reconstituted with bacteriostatic or sterile water (e.g., a 10 mg vial dissolved and blended into roughly 1 oz / 30 mL of a serum base to reach a topical working concentration). N/A as an injectable — SNAP-8 is used topically, not injected.

Injection sites

N/A — topical cosmetic application to the skin over expression-line areas (forehead, between the eyebrows/glabella, around the eyes, perioral). Not intended for injection.

Storage & handling

Sealed lyophilized powder is reported stable refrigerated (or frozen for longer) for many months. Reconstituted solution/serum is commonly kept refrigerated in an opaque or dark container to limit light degradation and used within roughly 3-8 weeks.

Side effects

• Mild local skin irritation or redness Mild · Uncommon
• Skin dryness or tightness at application site Mild · Uncommon
• Increased sensitivity when layered with retinoids or vitamin C Mild · Uncommon
• Contact dermatitis / allergic reaction Moderate · Rare
• Transient stinging on application Mild · Rare

Research summary

SNAP-8 is an eight-amino-acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2) that extends the design of Argireline (Acetyl Hexapeptide-8). Its proposed mechanism is competitive mimicry of the N-terminal of SNAP-25, a SNARE-complex protein involved in vesicle fusion and acetylcholine release at the neuromuscular junction; by occupying part of the SNARE assembly site it is theorized to modestly attenuate muscle contraction and thereby the depth of dynamic wrinkles. The bulk of the efficacy evidence base is manufacturer- and supplier-sponsored cosmetic testing rather than independent peer-reviewed clinical trials. Supplier literature commonly cites figures such as roughly 30% greater in-vitro activity than Argireline and wrinkle-depth reductions on the order of 30-60% after about 28 days of twice-daily topical use at concentrations around 3-10%, but these claims originate largely from in-house studies and are not well replicated in independent, peer-reviewed dermatology journals. The independent published literature is mostly analytical/pharmaceutical in nature (for example, an LC-MS/MS quantification method-development paper applied to a microneedle patch) rather than controlled efficacy trials. A key limitation is cutaneous penetration: as a relatively large, hydrophilic, charged peptide (MW ~1073 g/mol), meaningful delivery to the neuromuscular junction is biologically uncertain, and some observed smoothing may reflect surface hydration and film-forming effects. Reported tolerability is generally good, with adverse events typically limited to mild local irritation. Overall the human efficacy evidence is weak-to-moderate and predominantly commercial, and SNAP-8 is regulated and used as a cosmetic ingredient, not a drug.

Key references

• https://pubchem.ncbi.nlm.nih.gov/compound/71587832
• https://drugs.ncats.io/substance/8K14HJF88S
• https://doi.org/10.1186/s40543-020-00232-8
• https://www.caymanchem.com/product/27260/acetyl-octapeptide-3

Related compounds